SEC Form 4 · accession 0001209191-15-061952
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christopher Flint OBrien
Officer — Chief Medical Officer
Period of report
Jul 20, 2015
Accepted (ET)
Jul 21, 2015 · 8:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 20, 2015 | M | 11,250 | $5.76 | A | 111,294 | D | |
| Common Stock | Jul 20, 2015 | S | 11,250 | $55.00 | D | 100,044 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF2 | $5.76 | Jul 20, 2015 | M | 11,250 | D | — | Aug 25, 2021 | Common Stock | 11,250 | 83,750 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2The option was granted August 25, 2011 and vested in 36 equal monthly installments beginning September 25, 2011.